Sun Pharma Advanced Research Company Limited (NSE: SPARC)
India
· Delayed Price · Currency is INR 199.78
-1.51 (-0.75%)
Dec 26, 2024, 3:30 PM IST
NSE: SPARC Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 600.85 | 755.45 | 2,388 | 1,372 | 2,530 | 768.14 | Upgrade
|
| Revenue | 600.85 | 755.45 | 2,388 | 1,372 | 2,530 | 768.14 | Upgrade
|
| Revenue Growth (YoY) | -73.17% | -68.36% | 73.98% | -45.74% | 229.31% | -57.99% | Upgrade
|
| Cost of Revenue | 376.39 | 364.39 | 283.24 | 235.6 | 328.59 | 519.52 | Upgrade
|
| Gross Profit | 224.47 | 391.07 | 2,105 | 1,137 | 2,201 | 248.62 | Upgrade
|
| Selling, General & Admin | 2,948 | 2,944 | 2,390 | 1,658 | 1,457 | 1,355 | Upgrade
|
| Research & Development | 902.3 | 1,014 | 1,495 | 1,084 | 1,840 | 1,689 | Upgrade
|
| Other Operating Expenses | 393.09 | 426.59 | 339.19 | 254.38 | 253.45 | 260.44 | Upgrade
|
| Operating Expenses | 4,368 | 4,508 | 4,341 | 3,098 | 3,658 | 3,398 | Upgrade
|
| Operating Income | -4,143 | -4,117 | -2,236 | -1,961 | -1,457 | -3,150 | Upgrade
|
| Interest Expense | -23.55 | -11.75 | -76.35 | -133.29 | -106.5 | -26.75 | Upgrade
|
| Interest & Investment Income | 254.76 | 254.76 | 75.95 | 14.1 | 8.97 | 29.32 | Upgrade
|
| Currency Exchange Gain (Loss) | -28.99 | -28.99 | -20.69 | -8.39 | 30.14 | -45.37 | Upgrade
|
| Other Non Operating Income (Expenses) | -173.69 | -2.89 | 0.17 | 0.77 | 4.71 | 0.31 | Upgrade
|
| EBT Excluding Unusual Items | -4,115 | -3,906 | -2,257 | -2,088 | -1,520 | -3,192 | Upgrade
|
| Gain (Loss) on Sale of Investments | 31.81 | 31.81 | 32.65 | 4.64 | 5.67 | 66.71 | Upgrade
|
| Gain (Loss) on Sale of Assets | 5.82 | 5.82 | -1.13 | 48.93 | 2.64 | 1.29 | Upgrade
|
| Pretax Income | -4,077 | -3,868 | -2,226 | -2,034 | -1,511 | -3,124 | Upgrade
|
| Income Tax Expense | 9.42 | 3.82 | - | - | - | - | Upgrade
|
| Net Income | -4,087 | -3,872 | -2,226 | -2,034 | -1,511 | -3,124 | Upgrade
|
| Net Income to Common | -4,087 | -3,872 | -2,226 | -2,034 | -1,511 | -3,124 | Upgrade
|
| Shares Outstanding (Basic) | 325 | 325 | 285 | 263 | 262 | 262 | Upgrade
|
| Shares Outstanding (Diluted) | 325 | 325 | 285 | 263 | 262 | 262 | Upgrade
|
| Shares Change (YoY) | 4.38% | 13.99% | 8.19% | 0.42% | - | 2.52% | Upgrade
|
| EPS (Basic) | -12.59 | -11.93 | -7.82 | -7.73 | -5.77 | -11.92 | Upgrade
|
| EPS (Diluted) | -12.59 | -11.93 | -7.82 | -7.73 | -5.77 | -11.92 | Upgrade
|
| Free Cash Flow | -4,635 | -4,557 | -845.05 | -2,409 | -1,579 | -2,648 | Upgrade
|
| Free Cash Flow Per Share | -14.28 | -14.04 | -2.97 | -9.16 | -6.03 | -10.11 | Upgrade
|
| Gross Margin | 37.36% | 51.77% | 88.14% | 82.83% | 87.01% | 32.37% | Upgrade
|
| Operating Margin | -689.60% | -544.98% | -93.66% | -142.86% | -57.60% | -410.02% | Upgrade
|
| Profit Margin | -680.16% | -512.56% | -93.22% | -148.19% | -59.75% | -406.70% | Upgrade
|
| Free Cash Flow Margin | -771.36% | -603.21% | -35.39% | -175.53% | -62.42% | -344.79% | Upgrade
|
| EBITDA | -4,050 | -4,023 | -2,149 | -1,877 | -1,366 | -3,072 | Upgrade
|
| EBITDA Margin | - | - | -89.99% | -136.79% | -54.01% | - | Upgrade
|
| D&A For EBITDA | 93.89 | 93.69 | 87.74 | 83.25 | 90.88 | 77.47 | Upgrade
|
| EBIT | -4,143 | -4,117 | -2,236 | -1,961 | -1,457 | -3,150 | Upgrade
|
| EBIT Margin | - | - | -93.66% | -142.86% | -57.60% | - | Upgrade
|
| Revenue as Reported | 724.75 | 1,050 | 2,497 | 1,441 | 2,584 | 865.77 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.